Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Receives $24.00 Average Price Target from Analysts

Shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) have received a consensus rating of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $24.75.

Several equities research analysts recently weighed in on the stock. B. Riley Financial assumed coverage on shares of Unicycive Therapeutics in a research report on Friday, May 1st. They set a “buy” rating and a $22.00 price target for the company. Benchmark reiterated a “speculative buy” rating and set a $18.00 price target (up from $15.00) on shares of Unicycive Therapeutics in a research note on Tuesday. Guggenheim reiterated a “buy” rating and set a $37.00 price target (down from $40.00) on shares of Unicycive Therapeutics in a research note on Wednesday, May 13th. Wall Street Zen cut shares of Unicycive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Unicycive Therapeutics in a research note on Friday, March 27th.

Institutional Trading of Unicycive Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its stake in Unicycive Therapeutics by 11,698.4% in the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after purchasing an additional 21,525 shares during the last quarter. Lazard Asset Management LLC purchased a new position in shares of Unicycive Therapeutics during the second quarter worth $55,000. Vanguard Group Inc. raised its holdings in shares of Unicycive Therapeutics by 8.7% during the third quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock worth $2,873,000 after purchasing an additional 52,925 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in Unicycive Therapeutics during the third quarter valued at $512,000. Finally, Citadel Advisors LLC acquired a new stake in Unicycive Therapeutics during the third quarter valued at $182,000. 40.42% of the stock is owned by hedge funds and other institutional investors.

Unicycive Therapeutics Trading Down 0.4%

Unicycive Therapeutics stock opened at $7.20 on Friday. The business’s fifty day simple moving average is $7.30 and its two-hundred day simple moving average is $6.66. Unicycive Therapeutics has a 12 month low of $3.71 and a 12 month high of $11.00. The company has a market capitalization of $192.24 million, a price-to-earnings ratio of -3.26 and a beta of 1.73.

Unicycive Therapeutics (NASDAQ:UNCY) last released its earnings results on Tuesday, May 12th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.08). On average, equities research analysts predict that Unicycive Therapeutics will post -1.34 EPS for the current year.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.